FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4243363529> ?p ?o ?g. }

• W4243363529 endingPage "1667" @default.
• W4243363529 startingPage "1667" @default.
• W4243363529 abstract "ObesityVolume 26, Issue 11 p. 1667-1667 AnnouncementsFree Access Steven B. Heymsfield, MD: Incoming President, The Obesity Society, 2018-2019 First published: 25 October 2018 https://doi.org/10.1002/oby.22338AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL A native of New York City, Steven B. Heymsfield, MD, completed medical school at Mount Sinai School of Medicine in 1971. Following his training in internal medicine, Dr. Heymsfield began his clinical and research career as a faculty member at Emory University’s School of Medicine in 1973 and then moved on, in 1986, to successive academic positions at Columbia University’s College of Physicians and Surgeons. Following Columbia, in 2004, he first served as Executive Director of the clinical obesity franchise and then as Global Director of Scientific Affairs for the obesity group at Merck & Co. Dr. Heymsfield is currently professor and director of the Metabolism-Body Composition Laboratory at Pennington Biomedical Research Center in Baton Rouge, Louisiana, having served as the institution’s Executive Director between 2010 and 2013. Early in his career, while at Emory, Dr. Heymsfield introduced new nonvolitional feeding methods for managing malnourished hospitalized patients (1), and he centered his research around models of energy balance and body composition (2). He served as president of the American Society of Parenteral and Enteral Nutrition in 1984 and then as president of the American Society of Clinical Nutrition in 2001. Dr. Heymsfield increased his clinical and research focus on obesity while at Columbia, working with pioneers in the field including Theodore Van Itallie, Jules Hirsch, and Xavier PiSunyer. His interests there were wide-ranging, and, together with colleagues, he introduced new methods of quantifying human body composition and energy metabolism (3), was among the first to report commonly observed misreporting of calorie intake among patients with obesity (4), exposed the calorie mislabeling of foods served in public restaurants and by food vendors (5), served a pivotal role in the Food and Drug Administration’s ban on ephedra-containing dietary supplements (6), and published the first clinical study of leptin, a hormone discovered through the efforts of his colleagues at Rockefeller and Columbia universities (7). The clinical research programs he actively participated in at Merck & Co. have provided new insights into novel molecular targets and medicines (8) for moderating energy balance, disturbances of which are at the core of the obesity epidemic. With his long experience as a scientist and clinician, Dr. Heymsfield has played a key role in developing concepts advancing obesity as a complex disease (9), helping to dispel long-held misconceptions that excess adiposity simply reflects a person’s lack of willpower or self-control. Through these efforts and those of his colleagues, obesity is now recognized as a disease by the American Medical Association, The Obesity Society (TOS), and many other organizations across the globe. Dr. Heymsfield has written more than 600 peer-reviewed original papers, reviews, and commentaries on obesity, nutrition, and metabolism. He has been the recipient of multiple awards, including the TOS TOPS Award and the George A. Bray Founders Award. Dr. Heymsfield’s research has been supported by multiple organizations throughout his academic career, notably the National Institutes of Health. Dr. Heymsfield has ambitious plans as he assumes the presidency of TOS, including further strengthening the society’s role as the leading scientific organization devoted to the study of obesity across the life span. As part of that effort, Dr. Heymsfield will work with the Executive Director and Council to closely align the TOS vision, mission, and strategic plan (10) with the organization’s administrative, committee, and section structure. These reorganization efforts will improve the society’s efficiency, communication capabilities, and value to its members, notably those early in their academic careers. As a former leader of both an academic institution and an industry research group, Dr. Heymsfield recognizes the need to continue developing and expanding TOS partnerships with other societies and foundations as well as federal, state, and local research-based organizations, the public, and our industry colleagues. These efforts, which he will endeavor to facilitate, will proactively advance the TOS vision to “better understand, prevent, and treat obesity to improve the lives of those affected through research, education, and advocacy.” References 1Heymsfield SB, Bethel RA, Ansley JD, Nixon DW, Rudman D. Enteral hyperalimentation: an alternative to central venous hyperalimentation. Ann Intern Med 1979; 90: 63- 71. 2Wang Z, Wang ZM, Heymsfield SB. History of the study of human body composition: a brief review. Am J Hum Biol 1999; 11: 157- 165. 3Wang ZM, Pierson RN Jr, Heymsfield SB. The five-level model: a new approach to organizing body-composition research. Am J Clin Nutr 1992; 56: 19- 28. 4Lichtman SW, Pisarska K, Berman ER, et al. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. N Engl J Med 1992; 327: 1893- 1898. 5Allison DB, Heshka S, Sepulveda D, Heymsfield SB. Counting calories–caveat emptor. JAMA 1993; 270: 1454- 1456. 6 Issues Relating to Ephedra-Containing Dietary Supplements: Hearings Before the Subcommittee on Oversight and Investigations and the Subcommittee on Commerce, Trade, and Consumer Protection of the House of Representatives Committee on Energy and Commerce, 108th Congress, 1st Sess (2003). 7Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282: 1568- 1575. 8Erondu N, Gantz I, Musser B, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006; 4: 275- 282. 9Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med 2017; 376: 254- 266. 10 Mission & vision. The Obesity Society website. https://tosconnect.obesity.org/obesity/about/mission-vision. Updated 2018. Accessed August 23, 2018. Volume26, Issue11November 2018Pages 1667-1667 ReferencesRelatedInformation" @default.
• W4243363529 created "2022-05-12" @default.
• W4243363529 date "2018-10-25" @default.
• W4243363529 modified "2023-10-16" @default.
• W4243363529 title "Steven B. Heymsfield, MD: Incoming President, The Obesity Society, 2018‐2019" @default.
• W4243363529 cites W1964637461 @default.
• W4243363529 cites W2014284280 @default.
• W4243363529 cites W2079146706 @default.
• W4243363529 cites W2105673552 @default.
• W4243363529 cites W2116843182 @default.
• W4243363529 cites W2318584852 @default.
• W4243363529 cites W2575018533 @default.
• W4243363529 cites W4230787226 @default.
• W4243363529 doi "https://doi.org/10.1002/oby.22338" @default.
• W4243363529 hasPublicationYear "2018" @default.
• W4243363529 type Work @default.
• W4243363529 citedByCount "0" @default.
• W4243363529 crossrefType "journal-article" @default.
• W4243363529 hasBestOaLocation W42433635291 @default.
• W4243363529 hasConcept C15744967 @default.
• W4243363529 hasConcept C161191863 @default.
• W4243363529 hasConcept C162324750 @default.
• W4243363529 hasConcept C17744445 @default.
• W4243363529 hasConcept C187736073 @default.
• W4243363529 hasConcept C199539241 @default.
• W4243363529 hasConcept C2778805511 @default.
• W4243363529 hasConcept C2994514709 @default.
• W4243363529 hasConcept C41008148 @default.
• W4243363529 hasConcept C512399662 @default.
• W4243363529 hasConcept C71924100 @default.
• W4243363529 hasConcept C74909509 @default.
• W4243363529 hasConceptScore W4243363529C15744967 @default.
• W4243363529 hasConceptScore W4243363529C161191863 @default.
• W4243363529 hasConceptScore W4243363529C162324750 @default.
• W4243363529 hasConceptScore W4243363529C17744445 @default.
• W4243363529 hasConceptScore W4243363529C187736073 @default.
• W4243363529 hasConceptScore W4243363529C199539241 @default.
• W4243363529 hasConceptScore W4243363529C2778805511 @default.
• W4243363529 hasConceptScore W4243363529C2994514709 @default.
• W4243363529 hasConceptScore W4243363529C41008148 @default.
• W4243363529 hasConceptScore W4243363529C512399662 @default.
• W4243363529 hasConceptScore W4243363529C71924100 @default.
• W4243363529 hasConceptScore W4243363529C74909509 @default.
• W4243363529 hasIssue "11" @default.
• W4243363529 hasLocation W42433635291 @default.
• W4243363529 hasOpenAccess W4243363529 @default.
• W4243363529 hasPrimaryLocation W42433635291 @default.
• W4243363529 hasRelatedWork W2003784611 @default.
• W4243363529 hasRelatedWork W2182161600 @default.
• W4243363529 hasRelatedWork W2327244900 @default.
• W4243363529 hasRelatedWork W2748952813 @default.
• W4243363529 hasRelatedWork W2899084033 @default.
• W4243363529 hasRelatedWork W4243476210 @default.
• W4243363529 hasRelatedWork W4243987088 @default.
• W4243363529 hasRelatedWork W4247439988 @default.
• W4243363529 hasRelatedWork W2189545239 @default.
• W4243363529 hasRelatedWork W2486243433 @default.
• W4243363529 hasVolume "26" @default.
• W4243363529 isParatext "false" @default.
• W4243363529 isRetracted "false" @default.
• W4243363529 workType "article" @default.